new
assay
diagnosi
infecti
diseasesparticularli
use
molecular
technologieswil
revolution
infecti
diseas
practic
fulfil
promis
sever
year
away
problem
current
avail
molecular
assay
includ
lack
knowledg
extent
microbi
nucleic
acid
normal
host
concentr
agent
materi
small
volum
sampl
lack
microbiologist
expertis
lack
adequ
reimburs
difficulti
valid
base
convent
method
clinician
must
appreci
shortcom
new
technolog
use
effect
appropri
howev
realiz
tangibl
progress
abil
detect
new
etiolog
agent
avail
rapid
accur
diagnost
test
previous
difficult
infect
advanc
new
human
responsebas
paradigm
diagnost
test
promis
star
trekinspir
handheld
infecti
diseas
diagnost
devic
scan
patient
bodi
immedi
provid
inform
need
diagnosi
treatment
probabl
year
away
time
clinician
microbiologist
becom
unemploy
use
amaz
technolog
alreadi
avail
overview
discuss
select
technolog
provid
opinion
util
pitfal
summar
tabl
potenti
although
day
diagnost
microbiolog
laboratori
routin
use
molecular
tool
yet
come
mani
clinician
believ
plethora
test
readili
avail
laboratorian
regularli
ask
perform
pcr
test
detect
agent
publish
research
studi
report
studi
usual
describ
preliminari
result
physician
often
seem
surpris
laboratori
provid
servic
survey
american
societi
microbiolog
publish
provid
snapshot
current
environ
unit
state
laboratori
repres
commun
academ
commerci
laboratori
respond
survey
perform
bacteriolog
test
perform
molecular
test
infecti
diseas
bulk
latter
laboratori
offer
molecular
test
chlamydianeisseria
gonorrhoea
determin
basi
colleg
american
pathologist
survey
particip
summari
forese
futur
staf
financi
issu
mani
nonconsolid
nonacadem
hospit
laboratori
perform
new
hightechnolog
expens
skilldemand
assay
nation
shortag
clinic
laboratori
scientist
number
train
program
decreas
past
decad
qualifi
student
choos
career
medicin
comput
scienc
nurs
paid
dramat
clinic
laboratori
scientistsa
disincent
student
consid
laboratori
careeralthough
level
profession
dedic
patient
care
requir
overal
vacanc
rate
among
microbiolog
technologist
almost
onehalf
vacanc
requir
least
month
fill
staf
shortag
pipelin
unit
state
today
becom
worrisom
combin
age
current
experienc
staff
thirtyfour
percent
microbiologist
work
today
year
old
retir
next
year
compet
molecular
method
miniscul
howev
senior
microbiologist
interpret
gram
stain
deliv
educ
guess
identif
pathogen
earli
stage
infecti
diseas
clinician
reli
expert
worker
reliabl
molecular
diagnost
test
readili
avail
mani
infecti
agent
commerci
test
use
valid
specimen
type
transport
problem
low
concentr
infecti
agent
primer
bind
site
genet
chang
final
assay
volum
inhibit
contamin
nonspecif
amplif
oper
error
lead
falseneg
falseposit
amplif
result
genom
bacteri
sequenc
subject
error
sequenc
homolog
among
differ
bacteria
databas
problem
mutat
unknown
extent
microbi
dna
normal
host
tissu
lack
necessari
resourc
human
econom
reimburs
often
suffici
cover
cost
today
infecti
diseas
traine
still
train
laboratori
util
resourc
new
younger
laboratori
workforc
highli
skill
either
convent
hightech
environ
microbiologist
gener
short
suppli
face
knowledg
practic
gap
next
year
time
molecular
tool
gradual
fulfil
promis
even
laboratori
staf
skill
microbiologist
daytim
mani
critic
test
result
need
even
night
shift
laboratori
staf
nonspeci
laboratorian
result
physician
less
trust
test
result
need
make
greater
number
empir
decis
use
greater
number
broadspectrum
antimicrobi
agent
anoth
aspect
dearth
experienc
technologist
test
becom
instrument
base
disciplin
base
appar
migrat
hepat
hiv
serolog
test
microbiolog
virolog
depart
immunochemistri
laboratori
generalist
chemistri
technologist
perform
test
along
test
serum
factor
toxin
protein
tester
gener
knowledg
agent
test
could
lead
interpret
error
failur
recogn
inappropri
result
difficult
best
valid
test
result
assur
clinic
util
reliabl
reproduc
result
use
new
technolog
tradit
cultureor
antigenbas
compar
method
often
yield
result
fail
correl
newer
sensit
test
find
clinic
criteria
altern
molecular
target
verifi
result
correct
tediou
expens
occasion
imposs
obtain
adequ
standard
posit
patient
sampl
valid
test
result
train
perform
technologist
also
challeng
one
exampl
pcr
csf
specimen
herp
simplex
viru
meningoenceph
consid
best
diagnost
assay
avail
cultur
insensit
brain
biopsi
invas
difficulti
find
enough
sampl
creat
seed
sampl
known
viral
load
valid
studi
prevent
delay
develop
test
mani
laboratori
fact
ident
problem
imped
submiss
us
food
drug
administr
fda
approv
commerci
assay
herp
simplex
viru
analytespecif
reagent
test
kit
avail
herp
simplex
viru
enterovirus
still
requir
extens
inhous
valid
studi
threat
avian
influenza
pandem
may
help
spur
develop
multiplex
molecular
assay
respiratori
virus
use
laboratori
test
diagnosi
enterovir
cn
diseas
shown
cost
effect
long
ago
avail
rapid
molecular
test
purpos
long
come
mani
circumst
test
infecti
diseas
physician
heard
eg
nation
meet
infecti
diseas
societi
america
avail
sendout
test
referr
laboratori
accompani
attend
transport
problem
possibl
specimen
degrad
delay
result
cost
avail
molecular
test
perform
local
laboratori
one
import
benefitsrapid
resultsi
realiz
sampl
must
sent
distant
refer
laboratori
even
newest
gener
realtim
molecular
test
system
genexpert
test
group
b
streptococci
cepheid
slate
fda
clearanc
moder
complex
becom
avail
initi
cost
may
delay
widespread
implement
cours
wide
perform
molecular
method
hiv
load
nucleic
acid
amplif
naa
assay
chlamydia
trachomati
n
gonorrhoea
use
genit
sampl
urin
specimen
howev
mani
physician
assum
one
easili
test
eye
swab
cervic
swab
without
appreci
laboratori
must
perform
extens
valid
sampl
includ
origin
fda
clearanc
devic
report
issu
test
paid
mani
molecular
test
limit
refer
laboratori
research
investig
cours
new
technolog
nucleic
acid
base
also
discuss
method
number
nucleic
acid
hybrid
amplif
method
use
includ
direct
probe
hybrid
advandx
fish
staphylococcu
aureu
advandx
genprob
group
streptococci
genprob
hybrid
captur
digen
human
papillomaviru
digen
pcr
branchedchain
dna
bdna
bayer
diagnost
transcriptionmedi
amplif
probetec
chlamydia
n
gonorrhoea
becton
dickinson
sampl
volum
encompass
origin
sampl
volum
number
nucleic
acid
sequenc
present
final
amplifi
sampl
portion
transport
condit
dilut
factor
inhibitori
factor
genom
chang
instrument
problem
oper
error
contribut
falseposit
falseneg
test
result
even
close
system
detect
end
prevent
crosscontamin
posit
sampl
process
front
end
exampl
current
fda
restrict
requir
papanicola
smear
first
perform
singl
suspens
cervic
cell
receiv
preserv
request
cytolog
detect
human
papillomaviru
chlamydia
speci
n
gonorrhoea
contribut
common
find
insuffici
sampl
size
remain
infecti
diseas
test
papanicola
sampl
remov
unfortun
unlik
direct
visual
examin
sampl
qualiti
assess
neg
result
assay
includ
comment
qualiti
specimen
although
molecular
test
use
whole
blood
sampl
detect
agent
sepsi
yet
avail
sever
assay
develop
volum
factor
sensit
test
amount
bacteria
blood
obtain
patient
bacteremia
often
cfuml
yet
volum
use
naa
reaction
vial
ml
even
sampl
concentr
way
chanc
microbi
genet
materi
reach
reaction
vial
could
small
result
falseneg
result
sampl
contain
human
neutrophil
erythrocytesth
sampl
like
harbor
infecti
agentit
challeng
concentr
microbi
dna
without
also
ad
overwhelm
amount
human
somat
dna
avail
frontend
method
extract
filtrat
column
magnet
particl
captur
silicabas
system
still
lack
effici
manufactur
spend
energi
backend
technolog
detect
report
frontend
process
urgent
need
ideal
result
develop
creativ
new
method
concentr
cellrich
specimen
purul
fluid
blood
sputum
human
allow
sensit
detect
microbi
nucleic
acid
diagnosi
tubercul
mening
anoth
exampl
problem
inher
amplif
technolog
use
pcr
patient
may
confound
sign
symptom
number
organ
csf
sampl
may
low
convent
test
insensit
andor
slow
direct
acidfast
stain
csf
specimen
sensit
volum
csf
need
adequ
cultur
least
ml
prefer
ml
mycobacterium
tuberculosi
extrem
buoyant
csf
result
waxi
cell
wall
thu
concentr
centrifug
ineffici
smear
acidfast
bacilli
made
sediment
must
layer
examin
exhaustivelysometim
minin
hope
detect
rare
tuberculosi
rod
naa
would
seem
answer
sadli
naa
test
display
overal
sensit
rang
specif
rang
determin
metaanalysi
publish
studi
use
homebrew
individu
laboratorydevelop
valid
method
result
laboratori
use
commerci
avail
assay
evalu
separ
overal
sensit
decreas
rang
assay
like
avail
clinician
naa
result
equal
acidfast
bacilli
smear
clinician
must
realiz
unwant
relianc
new
technolog
may
lead
diagnost
error
anoth
highli
favor
technolog
laboratori
diagnosi
infecti
diseas
whether
test
tissu
directli
test
isol
coloni
identif
nucleic
acid
sequenc
also
pitfal
approach
exampl
mani
organ
although
may
antigen
biochem
distinct
virtual
genet
ident
member
bacteroid
fragili
group
exampl
highli
relat
separ
easili
standard
sequenc
method
clinician
realiz
escherichia
coli
shigella
speci
highli
relat
consid
difficulti
related
would
pose
reli
sequenc
identifi
genera
directli
patient
sampl
extent
share
gene
taxonom
versu
phenotyp
share
trait
among
microb
unknown
anoth
issu
vex
clinician
taxonom
confus
caus
genet
investig
rhinosporidium
seeberi
exampl
agent
mass
lesion
sinu
mucou
membran
organ
often
observ
histopatholog
section
never
grown
cultur
resembl
spherul
coccidioid
immiti
howev
long
consid
uncultur
fungu
recent
rrna
sequenc
place
organ
group
protozoan
fish
parasit
constantli
face
new
name
familiar
organismsand
even
new
organ
may
may
import
familiar
syndrom
moreextens
test
perform
newli
discov
mycoplasma
fermentan
origin
call
mycoplasma
incognitu
implic
gulf
war
syndrom
hiv
infect
later
found
quit
common
human
effect
therapi
result
pcr
genit
sampl
obtain
patient
c
trachomati
remain
posit
week
nucleic
acid
detect
probabl
viabl
know
extent
carriag
uncultur
microbi
normal
microbi
dna
healthi
host
cost
equip
expens
reagent
addit
skill
personnel
need
easi
justifi
exampl
fda
clear
realtim
pcr
test
group
b
streptococc
vaginalrect
colon
labor
widespread
use
test
could
negat
need
perform
cultur
pregnant
women
week
gestat
would
solv
problem
associ
treat
women
present
labor
without
screen
test
result
current
women
receiv
prophylact
penicillin
labor
number
would
decreas
women
pcr
result
posit
group
b
streptococci
labor
treat
problem
howev
current
recommend
alreadi
reduc
incid
earlyonset
neonat
group
b
streptococc
diseas
less
nation
health
object
case
per
live
birth
addit
improv
costeffect
lucil
packard
children
hospit
johnson
center
stanford
univers
medic
center
affili
campu
deliv
babi
annual
perform
pcr
assay
immedi
sampl
receiv
necess
assur
prophylaxi
administ
least
h
deliveri
would
staff
technologist
time
test
perform
take
min
handson
time
test
run
min
technologist
must
perform
continu
sampl
manag
twentyfourseven
staf
day
per
year
would
requir
clinic
laboratori
scientist
labor
overhead
cost
reagentsnot
count
cost
instrument
itselfcost
annual
total
yearli
cost
stanford
univers
medic
center
stanford
ca
patient
colon
rate
among
women
labor
result
babi
risk
per
year
prevent
potenti
group
b
streptococc
infect
use
test
cost
per
infect
avoid
would
hard
sell
hospit
administr
focus
bottom
line
potenti
laboratori
staff
labor
save
use
randomaccess
moder
complex
molecular
system
genexpert
mention
may
help
bring
cost
cost
new
technolog
often
ad
onto
exist
test
overal
diagnost
cost
increas
center
medicar
medicaid
servic
reimburs
lag
dramat
behind
use
new
test
northern
california
reimburs
area
laboratori
receiv
pcr
test
bordetella
pertussi
bordetella
parapertussi
although
cost
laboratori
test
sampl
test
alway
perform
one
specimen
time
necessit
test
addit
control
simultan
futur
bleak
cours
new
agent
import
diseas
discov
help
molecular
technolog
among
elucid
recent
tropheryma
whipplei
bartonella
hensela
ehrlichia
chaffeensi
mycoplasma
genitalium
infecti
diseaserel
challeng
readi
solut
new
molecular
tool
etiolog
case
pharyng
unknown
etiolog
case
diarrhea
unknown
etiolog
case
pneumonia
cultiv
organ
subgingiv
crevic
patient
periodont
diseas
mysteri
regard
vex
syndrom
eventu
yield
molecular
technolog
proteom
ie
profil
protein
gener
human
cell
respons
variou
stimuli
includ
compon
product
infecti
agent
infanc
excit
develop
entic
spot
dna
rna
gene
chip
design
homolog
nucleic
acid
sequenc
sampl
repres
nucleic
acid
found
normal
situat
activ
state
transcript
repres
variou
genet
sequenc
uniqu
vast
array
microb
detect
infecti
agent
sampl
treat
break
dna
rna
small
discret
sequenc
ident
sequenc
exist
chip
sampl
nucleic
acid
find
match
bind
emit
electron
signal
humanrespons
chip
use
determin
patient
respons
potenti
toxic
antimicrobi
treatment
advanc
deliveri
patient
lack
enzym
break
toxin
metabol
drug
effect
altern
therapi
use
avoid
danger
advers
effect
anoth
prospect
microarraybas
test
human
leukocyt
respons
variou
infecti
agent
may
use
pinpoint
etiolog
agent
detect
develop
sort
technolog
fast
track
facilit
detect
bioterror
agent
symptomat
phase
diseas
render
widespread
prevent
measur
inadequ
proteom
use
finetun
develop
new
antiinfect
well
one
aspect
microarray
technolog
yet
standard
codifi
monument
problem
data
analysi
entir
new
disciplin
bioinformat
develop
purpos
challeng
interpret
vast
volum
data
point
gener
microarray
studi
acquir
along
technolog
advanc
resolut
requir
collect
extens
effort
summari
futur
potenti
util
incred
technologiesand
numer
other
mention
herewil
revolution
infecti
diseas
diagnost
howev
shortcom
technolog
must
recogn
present
danger
includ
failur
support
need
tradit
train
microbiologist
allow
expertis
move
site
distant
patient
care
activ
inappropri
trust
new
technolog
underestim
valu
clinic
diagnosi
base
acumen
experienc
laboratorian
infecti
diseas
practition
